Finanzen von ProQR Therapeutics NV (PRQR)PRQRProQR Therapeutics NV

Evaluating the bottom line, ProQR Therapeutics NV maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -100.72%, while the net margin is -99.65%. These profitability ratios, combined with a Return on Equity (ROE) of -57.40%, provide a clear picture of how effectively PRQR converts its operational activities into shareholder value.

In the context of the broader market, PRQR competes directly with industry leaders such as VNDA and IMRX. With a market capitalization of $323.17M, it holds a significant position in the sector. When comparing efficiency, PRQR's gross margin of 100.00% stands against VNDA's 89.02% and IMRX's N/A. Such benchmarking helps identify whether ProQR Therapeutics NV is trading at a premium or discount relative to its financial performance.

ProQR has shown significant revenue growth, with Q2 2026 revenue at 8,759,000 EUR, up from 2,033,000 EUR in Q1 2026. However, the company continues to report negative net income, with a net loss of -8,728,000 EUR in Q2 2026.